Augmentation of cisplatin with thymoquinone to target chemoresistant ovarian cancer in vitro study

Abstract

Background: Ovarian cancer (OvCa) is the leading gynecological cancer and has been reported to have multi-drug resistance. Due to poor prognosis, women have low survival rates and therapies have negative impacts on the quality of life. Resistance to conventional treatments such as chemotherapy and radiation therapy is the reason for the need for innovative therapies. Phytochemicals (PCs) have demonstrated significant potential in the field of OvCa by inhibiting metastasis of cancer cells. Thymoquinone (TQ) is a promising drug in the field of OvCa for inhibiting the cell proliferation of cancer cells. Objectives: The study demonstrates cisplatin (CDDP)- induced chemoresistance in OvCa using in-vitro assays. The study also determines the anti-chemoresistance mechanisms of CDDP along with TQ in OvCa.